

Market Outlook

The Nifty 50 closed at 25,694, marking a positive session. On the daily chart, the index demonstrated resilience near the 25,400 zone and staged a strong rebound, successfully reclaiming the 20-day EMA. In the derivatives segment, fresh Put OI build-up at the 25,500 and 25,600 strikes for the upcoming weekly expiry indicates a firm near-term support base. On the upside, Call OI accumulation at the 25,800 and 26,000 strikes highlights the immediate resistance levels to watch.

Key Indices Update

INDEX	CLOSE	CHANGE (%)
NIFTY	25694.95	0.47
SENSEX	83871.32	0.40
BANKNIFTY	58138.15	0.35
INDIA VIX	12.49	1.54

Fills STATISTICS


Fills F&O Data

Sector	Buy/Sell	Change in OI
Index Futures	-612.00	1.07%
Index Options	9016.47	-36.34%
Stock Futures	21.14	-0.14%
Stock Options	206.11	3.50%

Fills & DII's Cash Segment (Rs. In Crore)

Category	Amount	MTD	YTD
FII	-803.22	-6551	-116771
DII	2188.47	24671	467121

Fills Activity in Index Future



Amt in Crores


NIFTY 50 HIGH DELIVERY STOCKS

SYMBOL	DELIVERABLE QTY	CHG IN DLY RATIO VS PREV DAY	% CHG IN TRD QTY OVER PREV DAY
ETERNAL	24280544	20.18	26.04
HDFCBANK	11329554	-0.25	6.56
POWERGRID	7010409	-7.77	-5.81
ICICIBANK	6119354	6.64	10.66
INFY	5871349	-6.35	11.66
BHARTIARTL	5484860	-8.68	-89.41
SHRIRAMFIN	5169289	11.33	-11.69
JIOFIN	4508543	0.58	-5.28
WIPRO	4425382	-0.08	55.18
RELIANCE	4298505	-0.21	-9.63


NIFTY

Nifty	25811.40
OI (In contracts)	269168
CHANGE IN OI (%)	0.20
PRICE CHANGE (%)	0.90
IMPLICATION	LONG BUILDUP

NIFTY (CLOSE VS OI)



NIFTY OPTION CHAIN




Long Buildup

Symbol	Price	Price %	OI	OI %
TECHM	1415.1	1.60	36179	11.50
NYKAA	260.07	6.00	20581	11.00
AMBER	7122	2.80	15764	8.20
SRF	2945.4	1.30	18089	7.80
RVNL	315.65	0.10	30036	6.90


BANKNIFTY

Banknifty	58370.80
OI (In contracts)	61214
CHANGE IN OI (%)	7.00
PRICE CHANGE (%)	0.30
IMPLICATION	LONG BUILDUP

BANKNIFTY (CLOSE VS OI)



BANKNIFTY OPTION CHAIN



Short Buildup

Symbol	Price	Price %	OI	OI %
FORTIS	989.3	-3.30	15876	18.40
TRENT	4335.1	-6.50	95950	14.10
VOLTAS	1296.2	-1.20	42668	11.20
SIEMENS	3037.1	-0.10	20875	10.90
LICI	904.6	-2.60	15445	10.60

Top 10 High PCR Ratio Stocks

SCRIP	PUT	CALL	P/C RATIO
BPCL	19955400	16317450	1.22
NATIONALUM	41317500	35703750	1.16
POWERINDIA	333600	286650	1.16
BHEL	47236875	41194125	1.15
PETRONET	15071400	13411800	1.12
SHRIRAMFIN	20080500	17933850	1.12
JINDALSTEL	5745625	5243125	1.1
AUBANK	6743000	6341000	1.06
IOC	59504250	56559750	1.05
CANBK	107466750	104375250	1.03

Top 10 Low PCR Ratio Stocks

SCRIP	PUT	CALL	P/C RATIO
BLUESTARCO	826150	2919150	0.28
GMRAIRPORT	42184800	134359425	0.31
DALBHARAT	532025	1585675	0.34
DELHIVERY	9405975	27437725	0.34
NESTLEIND	2002500	5917000	0.34
SHREECEM	51625	152275	0.34
ONGC	18371250	52420500	0.35
YESBANK	176959000	472004700	0.37
KFINTECH	1607750	4194000	0.38
PPLPHARMA	5887500	15365250	0.38

NIFTY 50 SUPPORT-RESISTANCE LEVELS

SYMBOL	R1	R2	PP	S1	S2
ADANIENT	2391	2409	2367	2349	2326
ADANIPORTS	1495	1509	1468	1453	1426
APOLLOHOSP	7592	7660	7527	7459	7394
ASIANPAINT	2673	2689	2653	2638	2617
AXISBANK	1234	1240	1225	1219	1210
BAJAJ-AUTO	9012	9101	8883	8794	8664
BAJAJFINSV	2084	2174	2021	1931	1868
BAJFINANCE	1043	1076	1022	989	968
BEL	433	436	426	422	415
BHARTIARTL	2070	2088	2047	2029	2007
CIPLA	1525	1532	1518	1511	1504
COALINDIA	386	388	383	381	378
DRREDDY	1220	1226	1211	1206	1196
EICHERMOT	6954	7005	6867	6816	6729
ETERNAL	310	313	306	303	299
GRASIM	2798	2814	2773	2756	2731
HCLTECH	1585	1596	1566	1555	1536
HDFCBANK	1000	1005	991	986	977
HDFCLIFE	771	777	760	754	743
HINDALCO	803	809	793	787	776
HINDUNILVR	2444	2454	2428	2419	2403
ICICIBANK	1367	1372	1358	1353	1344
INDIGO	5871	5942	5743	5672	5545
INFY	1520	1528	1507	1499	1485
ITC	410	411	408	406	405

SYMBOL	R1	R2	PP	S1	S2
JIOFIN	310	313	304	301	295
JSWSTEEL	1214	1234	1192	1172	1150
KOTAKBANK	2106	2116	2095	2085	2074
LT	3990	4015	3950	3925	3885
M&M	3793	3827	3735	3700	3642
MARUTI	15750	15817	15651	15584	15485
MAXHEALTH	1113	1125	1100	1088	1075
NESTLEIND	1278	1284	1267	1261	1251
NTPC	329	331	326	325	322
ONGC	254	258	251	247	243
POWERGRID	271	272	268	267	264
RELIANCE	1507	1514	1497	1490	1479
SBILIFE	2004	2012	1993	1985	1975
SBIN	962	966	955	951	944
SHRIRAMFIN	843	853	826	816	798
SUNPHARMA	1731	1740	1715	1706	1690
TATACONSUM	1167	1176	1153	1144	1130
TATASTEEL	183	185	181	180	178
TCS	3073	3086	3052	3039	3018
TECHM	1422	1429	1410	1403	1392
TITAN	3845	3870	3803	3778	3735
TMPV	414	420	408	402	396
TRENT	4385	4435	4335	4285	4235
ULTRACEMCO	11923	11970	11841	11794	11712
WIPRO	244	245	242	241	238

Research Team

Name	Email ID
<i>Ajit Mishra</i>	ajit.mishra@religare.com
<i>Abhijeet Banerjee</i>	abhijeet.banerjee@religare.com
<i>Gaurav Sharma</i>	gauravsharma2@religare.com
<i>Ashwani Harit</i>	ashwani.harit@religare.com
<i>Divya Parmar</i>	divya.parmar@religare.com
<i>Rajan Gupta</i>	rajan.gupta1@religare.com
<i>Vivek Chandra</i>	vivek.chandra@religare.com
<i>Himanshu Gupta</i>	himanshu.gupta1@religare.com
<i>Vishvajeet Singh</i>	vishvajeet.singh1@religare.com

Disclaimer

Before you use this research report, please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: <https://www.religareonline.com/disclaimer>

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

Statements on ownership and material conflicts of interest, compensation– Research Analyst (RA) [Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) below, are given separately]:

S. No.	Statement	Answer	
		Yes	No
	I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of Interest is given below this table]		No
	I/we or any of my/our relatives, have actual/beneficial ownership of one percent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No
	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?		No
	I/we have received any compensation from the subject company in the past twelve months?		No
	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No
	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No
	I/we have served as an officer, director or employee of the subject company?		No
	I/we have been engaged in market making activity for the subject company?		No

Nature of Interest if answer to F(a) above is Yes:

..... Name(s) with Signature(s) of RA(s).

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) above, are given below]

SS. No.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results